Perampanel is a drug used to treat patients with epilepsy/seizures. This study is designed to determine how much perampanel actually crosses the blood brain barrier into the cerebral spinal fluid when the drug is taken.
During a routinely scheduled neurosurgical procedure, one to two mL of cerebral spinal fluid will be obtained from the subarachnoid space of the brain. Five mL of arterial blood will also be drawn from the patients arterial line during their procedure. The blood samples and cerebral spinal fluid samples will be compared to see how much perampanel is in the blood versus the cerebrospinal fluid.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults (\>18 years-old) who are scheduled to undergo brain surgery and need antiepileptic medication for prophylaxis or treatment of seizures
Able to provide informed consent
You may not be if
Patient unable to provide informed consent
Allergy to PER or its component
Patient with significant renal (creatinine clearance 35 ml/min) or hepatic impairment
Pregnant or lactating females will be excluded from the study.
